- Email:
Retinal Organoid Service
Introduction
The retina is a complex CNS tissue targeted by regenerative medicine. Species differences limit traditional research, and human retinal organoids with microglia are vital for modelling retinal stress and degeneration. Creative Biolabs offers a professional Retinal Organoid Service using its 3D‑RET protocol and microglia‑integrated Armed Retina system. The service reconstructs human retinal structure, supports disease modelling and drug screening for multiple retinopathies, and provides reliable preclinical data to accelerate ophthalmic drug development.
Discover How We Can Help - Request a Consultation →
Retinal Organoid Service
The retina is a light-sensitive neural tissue that converts visual signals into electrical impulses for vision. Dysfunction leads to severe vision loss and blindness. Our Retinal Organoid Service generates human iPSC-derived 3D retinal organoids that recapitulate retinal development, layered cytoarchitecture, and light-responsive function, providing a human-relevant platform for ophthalmic disease modeling, drug discovery, and vision restoration research.
Fig.1 Distribution of immune cells within retina and composition of BRB.1,3
Key Cell Types & Markers
| Cell Type | Markers |
|---|---|
| Photoreceptors (rods/cones) | Recoverin, Rho, OPN1SW/LW/MW |
| Retinal pigment epithelium (RPE) | RPE65, MITF, ZO‑1 |
| Retinal ganglion cells | BRN3A, TUJ1 |
| Bipolar, horizontal, amacrine cells | PKCα, Calbindin, GAD67 |
| Retinal progenitor cells | VSX2, PAX6, LHX2 |
Core Differentiation Strategy
- Dual SMAD inhibition to induce retinal neuroectoderm
- Wnt and Hedgehog modulation for optic cup patterning
- Long-term maturation to form photoreceptor outer segments
- Millifluidic or suspension culture for structural stability
Quality Control Indicators
- Typical retinal layered structure formation
- Photoreceptor maturation and light responsiveness
- RPE integrity and barrier function
- Size uniformity and batch-to-batch reproducibility
- Synaptic connectivity and electrophysiological activity
Main Applications
- Modeling retinitis pigmentosa, AMD, diabetic retinopathy, and inherited retinal dystrophies
- Drug efficacy, neuroprotection, and retinal toxicity screening
- Gene therapy and cell replacement therapy evaluation
- Retinal development, circuit formation, and regeneration studies
Workflow
Our systematic approach ensures that every project is tailored to specific research goals, providing a clear path from initial cell reprogramming to final functional analysis.
What We Can Offer
As a global leader in advanced cell technologies, Creative Biolabs provides a suite of customized solutions designed to bring industrial-scale precision to organoid research. Our "Armed Retina" technology is backed by a rigorous quality system and high-capacity production capabilities.
One-stop Organoid Service
From laboratory-scale research pilots to large-scale, batch-consistent production for industrial screening.
Customized Genetic Engineering
Expert codon optimization and CRISPR/Cas9 gene-editing to create stable, disease-specific hiPSC banks.
Large-scale Culture Capability
Well-established infrastructure capable of maintaining hundreds of synchronized organoids across multiple developmental stages.
Proprietary 3D-RET Optimization
Optimized culture conditions and media formulations to maximize the yield of specific cell types, such as S-cones or RGCs.
Strict Quality-by-Design (QbD)
Documentation quality and differentiation procedures are assessed through a qualified quality assurance system to guarantee morphological stability.
High-Standard QC Tools
Integration of Process Analytical Techniques (PAT) and advanced imaging to quantify and evaluate the structural maturity of every batch.
HACCP & GMP Principles
We follow strict aseptic verification and basic principles of Good Manufacturing Practice to ensure the reliability of our in vitro models.
Experience the Creative Biolabs Advantage - Get a Quote Today →
Case Study
To investigate the effect of hyperglycemia on retinal organoids, researchers treated them at different differentiation stages (D30, D90, D150) with high glucose, L-glucose as osmotic control, and normal medium for 28 days, and validated the suitability of mannitol versus L-glucose as controls. They examined morphology, pro-apoptotic gene expression, retinal developmental marker expression, and protein localization. The results showed that hyperglycemia at early stages (D30+28, D90+28) did not alter organoid morphology, gene expression, apoptosis, or protein distribution, demonstrating that early retinal differentiation is resistant to hyperglycemic stress.
Fig.2 Investigate the impact of high glucose environment on the early differentiation of retinal organoids.2,3
Customer Reviews
FAQs
Q1: How do your retinal organoids compare to animal models in terms of drug response?
A: Our human-derived organoids eliminate species-specific discrepancies, particularly in GPCR signaling and immune response, providing data that more accurately predict human clinical outcomes.
Q2: Can you provide organoids at specific developmental stages?
A: Yes. We can deliver organoids ranging from early-stage RPC-rich clusters to late-stage mature tissues with developed photoreceptor outer segments, depending on your experimental needs.
Q3: Are these organoids suitable for gene therapy (AAV/CRISPR) testing?
A: Yes. They are an ideal substrate for assessing viral transduction efficiency, promoter specificity, and potential off-target effects in a multicellular human context.
Q4: Do you offer custom genetic modifications for disease modeling?
A: Yes, we can utilize CRISPR/Cas9 to introduce specific mutations or reporter genes into the hiPSC lines before differentiation to create bespoke disease models.
Q5: What are the storage requirements upon delivery?
A: We provide detailed protocols for immediate transfer to controlled CO2 incubators. Our specialized shipping media ensures high viability during transit.
Creative Biolabs provides an end-to-end solution for retinal research, encompassing hiPSC differentiation, microglial integration, and all-side phenotypic analysis. Our platform is designed to transform the speed and accuracy of ophthalmic drug discovery by providing a bio-realistic human alternative to traditional testing methods.
Contact Our Team for More Information and to Discuss Your Project →
References
- Liu, Yaohong, et al. ""Armed in-vitro retina"-generating microglial retinal organoids, where are we now?." Frontiers in Cell and Developmental Biology 13 (2025): 1574283. https://doi.org/10.3389/fcell.2025.1574283.
- Polešovská, Lada, et al. "Unveiling the cellular and molecular mechanisms of diabetic retinopathy with human retinal organoids." Cell Death & Disease 16.1 (2025): 892. https://doi.org/10.1038/s41419-025-08244-1.
- Distributed under Open Access license CC BY 4.0, without modification.
For Research Use Only. Not For Clinical Use.